LAVA Therapeutics NV
(FRA:4PKB)
€
1.61
-0.06 (-3.59%)
Market Cap: 43.42 Mil
Enterprise Value: -32.23 Mil
PE Ratio: 0
PB Ratio: 1.13
GF Score: 49/100 LAVA Therapeutics NV at Jefferies London Healthcare Conference Transcript
Nov 17, 2022 / 08:00AM GMT
Release Date Price:
€4.76
(+8.18%)
Unidentified Analyst
Excellent. Welcome, everyone, to the final days of the Jefferies London Healthcare Conference. I hope it's been an incredibly productive conference for you all, and you have a productive last day. Today, it's my pleasure to invite LAVA Therapeutics to a fireside chat. I'd like to introduce the CEO, Steve Hurly; and CMO, Benjamin Winograd.
Gentlemen, how are you doing today?
Steve Hurly
LAVA Therapeutics N.V. - President & CEO
Doing really well. Appreciate you, guys, having us.
Benjamin Winograd
LAVA Therapeutics N.V. - Chief Medical Officer
Great. Thanks.
Questions & Answers
Unidentified Analyst
Excellent. And so just get kicked off, I was curious what is a gamma delta bispecific T cell engager? It's quite a mouthful.
Steve Hurly
LAVA Therapeutics N.V. - President & CEO
Yeah. It's a practice makes perfect one pronunciation, enunciation. So we at LAVA, our foundation technology is bispecifics to
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot